Billionaire Warren Buffett's company has revealed a new investment in struggling Israeli drugmaker Teva Pharmaceuticals and trimmed its holdings in oil refiner Phillips 66 by selling 35 million shares back to the company for US$3.3 billion ($4.5b).
Berkshire Hathaway disclosed those moves and several other tweaks to its stock holdings in documents filed with the Securities and Exchange Commission. Berkshire said it held 18.9 million shares of Teva at the end of the year, worth about US$360 million.
Teva, the world's No. 1 generic drugmaker, this week detailed a two-year timeline for turning its business around after being hit by competition in its core generic business, the loss of patent protection on its multiple sclerosis drug Copaxone and a more than US$30b debt load from its acquisition of Allergan's generics business. It said in December it planned to cut 14,000 jobs, more than one quarter of its global workforce.
Berkshire Hathaway and Phillips 66 said the repurchase will let Buffett's company reduce its investment below the 10 per cent level that triggers additional regulations. That transaction was expected to close today.
Buffett, known as the Oracle of Omaha, said Berkshire plans to continue holding Phillips 66 stock long term. After this, Berkshire will hold 45.7 million shares, or about 9.8 per cent of the Houston-based refiner.